LTR Pharma has officially debuted on the Australian Securities Exchange (ASX) under ticker code LTP.
Our foremost priority is to execute a bioequivalence trial of SPONTAN® to support expedited regulatory approvals, and to market and sell SPONTAN in the United States and Australia, first.
We have a highly experienced team of pharmaceutical developers and commercialisation experts driving this program forward – and valued investors backing us too.
Successful phase I human proof of concept study now complete. SPONTAN® has shown to be six times faster than oral PDE5 inhibitors.
On track to register the first PDE5 inhibitor nasal spray, in a market estimated to reach US$6.0B in 2028.
Progressing to bioequivalence study, with expedited regulatory filings in the United States and Australia within 1-2 years.
View our Shareholder Communications summary here
View our Corporate Directory here
LTR Pharma is pleased to announce that SPONTAN® is now available through TerryWhite Chemmart’s network of 600+ pharmacies nationwide, marking a pivotal milestone in our
LTR Pharma has announced that it has entered into a collaborative development agreement with Strategic Drug Solutions, Inc. (SDS) to co-develop OROFLOW®, a novel intranasal
In our latest Conversation Series video, we meet Steve Jones – a prostate cancer survivor whose candid story highlights the profound psychological impact of erectile
9/204 Alice Street, Brisbane QLD 4000
Phone: 1800 519 711